Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 600 of 1631 entries
View as:

A Study to Learn More About What Japanese Patients With Solid Tumors Think About Taking Medicine That is Based on Their Genetic Information

Phase: N/A Priority: Normal
NCT ID: NCT04607889 Org: User:
Start: 12/15/20 End: 09/15/22 Due: 09/15/23

A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)

Phase: N/A Priority: Normal
NCT ID: NCT05900388 Org: User:
Start: 12/31/25 End: 06/30/29 Due: 06/30/30

A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06511973 Org: User:
Start: 07/23/24 End: 08/20/24 Due: 08/20/25

A Study to Learn More About the Safety of Ultravist in Children and in the Elderly

Phase: N/A Priority: Normal
NCT ID: NCT04605471 Org: User:
Start: 10/31/20 End: 03/31/21 Due: 03/31/22

RDEA119 and Sorafenib Combination Dose Escalation Study

Phase: N/A Priority: Normal
NCT ID: NCT00785226 Org: User:
Start: 11/30/08 End: 04/30/12 Due: 04/30/13

A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

Phase: N/A Priority: Normal
NCT ID: NCT05915026 Org: User:
Start: 08/16/23 End: 10/16/24 Due: 10/16/25

Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients

Phase: N/A Priority: Normal
NCT ID: NCT02617550 Org: User:
Start: 11/18/15 End: 08/11/16 Due: 08/11/17

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

Phase: N/A Priority: Normal
NCT ID: NCT02564718 Org: User:
Start: 11/19/15 End: 12/18/17 Due: 12/18/18

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Phase: N/A Priority: Normal
NCT ID: NCT04597125 Org: User:
Start: 11/09/20 End: 10/22/26 Due: 10/22/27

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00865709 Org: User:
Start: 03/31/09 End: 02/29/12 Due: 02/28/13

Evaluation of the Irritation Potential of Products in Human Eyes

Phase: N/A Priority: Normal
NCT ID: NCT02714166 Org: User:
Start: 02/26/16 End: 02/26/16 Due: 02/26/17

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Phase: N/A Priority: Normal
NCT ID: NCT06498921 Org: User:
Start: 07/15/24 End: 09/15/24 Due: 09/15/25

To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02312973 Org: User:
Start: 01/14/15 End: 06/01/16 Due: 06/01/17

Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

Phase: N/A Priority: Normal
NCT ID: NCT00845338 Org: User:
Start: 02/28/07 End: 10/31/07 Due: 10/31/08

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Phase: N/A Priority: Normal
NCT ID: NCT02313909 Org: User:
Start: 12/23/14 End: 02/15/18 Due: 02/15/19

Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02347852 Org: User:
Start: 01/20/15 End: 09/08/16 Due: 09/08/17

A Cross-sectional Study for the Determination of the Prevalence of Non-valvular Atrial Fibrillation Among Patients Diagnosed With Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02585076 Org: User:
Start: 11/04/15 End: 05/30/16 Due: 05/30/17

Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01031199 Org: User:
Start: 01/31/09 End: 12/31/09 Due: 12/31/10

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Phase: N/A Priority: Normal
NCT ID: NCT01516814 Org: User:
Start: 02/29/12 End: 11/30/13 Due: 11/30/14

Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT00658177 Org: User:
Start: 06/30/03 End: 02/29/04 Due: 02/28/05

Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life

Phase: N/A Priority: Normal
NCT ID: NCT01595724 Org: User:
Start: 05/31/12 End: 05/31/15 Due: 05/31/16

Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold

Phase: N/A Priority: Normal
NCT ID: NCT01361399 Org: User:
Start: 11/30/04 End: 05/28/05 Due: 05/28/06

A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00449033 Org: User:
Start: 02/28/07 End: 06/30/11 Due: 06/30/12

Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years

Phase: N/A Priority: Normal
NCT ID: NCT00250640 Org: User:
Start: 04/30/05 End: 07/31/12 Due: 07/31/13

Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)

Phase: N/A Priority: Normal
NCT ID: NCT02818998 Org: User:
Start: 11/16/16 End: 09/24/19 Due: 09/24/20